首页> 外文期刊>African Journal of Pharmacy and Pharmacology >Brazilein overcame ABCB1-mediated multidrug resistance in human leukaemia K562/AO2 cells
【24h】

Brazilein overcame ABCB1-mediated multidrug resistance in human leukaemia K562/AO2 cells

机译:巴西青霉素克服了人白血病K562 / AO2细胞中ABCB1介导的多药耐药性

获取原文
获取外文期刊封面目录资料

摘要

Multidrug resistance (MDR) was still a major obstacle to the success of chemotherapy in cancer treatment. One of the underlying mechanisms of MDR was cellular overexpression of ABCB1 transporter which pumped various anticancer drugs out of the cells. Here, we investigated the anticancer activity of brazilein (a compound isolated from?Caesalpinia sappanLinn.) against human leukaemia K562 and ABCB1 overexpression K562/AO2 cells. Cytotoxicity of brazilein was examined using 3-(4, 5-dimethylthiazol-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. FITC-Annexin V/PI staining was used to detect apoptotic cells. The expression of ABCB1 was determined by western blotting and RT-PCR assays, respectively. Flow cytometry was used to determine the intracellular accumulation of doxorubicin. The ATPase activity of ABCB1 was estimated using Pgp-Glo? Assay Systems. MTT and apoptotic analysis showed that brazilein exerted similar cytotoxicity against K562 and K562/AO2 cells. The IC50?values were 5.45 ± 0.36 and 5.62 ± 0.43 μmol/L for K562 and K562/AO2 cells, respectively. Western blotting and RT-PCR assays showed that brazilein did not affect the expression of ABCB1 in K562/AO2 cells. The fluorescence intensity assay demonstrated that brazilein did not promote the intracellular accumulation of doxorubicin. Luminescent ATPase assays proved that brazilein did not interfere with the ATPase of ABCB1. Our results showed that brazilein was not a substrate of ABCB1 and escaped the excretion of ABCB1 transporter to overcome ABCB1-mediated MDR. The present data suggested that brazilein would be promising to develop as an anticancer candidate for circumventing multidrug resistance.
机译:多药耐药性(MDR)仍然是化学疗法在癌症治疗中取得成功的主要障碍。 MDR的潜在机制之一是ABCB1转运蛋白的细胞过表达,该蛋白将各种抗癌药物泵出细胞。在这里,我们研究了巴西青霉素(从巴西?草中分离出的化合物)对人白血病K562和ABCB1过表达K562 / AO2细胞的抗癌活性。使用3-(4,5-二甲基噻唑基)-2,5-二苯基溴化四氮唑(MTT)测定法检测巴西吡嗪的细胞毒性。 FITC-Annexin V / PI染色用于检测凋亡细胞。分别通过蛋白质印迹和RT-PCR测定来确定ABCB1的表达。流式细胞仪用于确定阿霉素的细胞内积累。使用Pgp-Glo?估计ABCB1的ATPase活性。分析系统。 MTT和凋亡分析表明,巴西利辛对K562和K562 / AO2细胞具有相似的细胞毒性。 K562和K562 / AO2细胞的IC50值分别为5.45±0.36和5.62±0.43μmol/ L。 Western印迹和RT-PCR分析表明,巴西立素不影响K562 / AO2细胞中ABCB1的表达。荧光强度测定表明,巴西唑啉不促进阿霉素的细胞内积累。发光ATPase检测证明巴西来灵不干扰ABCB1的ATPase。我们的结果表明,巴西唑不是ABCB1的底物,可以逃避ABCB1转运蛋白的排泄,以克服ABCB1介导的MDR。目前的数据表明,巴西来灵有望成为开发抗多种药物耐药性的抗癌药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号